{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+Age-Related+Macular+Degeneration&page=2",
    "query": {
      "condition": "Neovascular (Wet) Age-Related Macular Degeneration",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+Age-Related+Macular+Degeneration&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T05:48:45.786Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01624636",
      "title": "Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LFG316",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 1,
      "start_date": "2012-12",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624636"
    },
    {
      "nct_id": "NCT06184360",
      "title": "Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neovascular (Wet) Age-related Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2079,
      "start_date": "2022-05-31",
      "completion_date": "2022-12-16",
      "has_results": false,
      "last_update_posted_date": "2023-12-28",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06184360"
    },
    {
      "nct_id": "NCT01997164",
      "title": "Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (\"Wet\") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "REGN910-3",
          "type": "DRUG"
        },
        {
          "name": "REGN910",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-11",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-01-12",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01997164"
    },
    {
      "nct_id": "NCT04635800",
      "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Edema",
        "Diabetic Macular Edema",
        "Neovascular Age-related Macular Degeneration",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "MHU650",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 21,
      "start_date": "2020-12-10",
      "completion_date": "2022-05-24",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 5,
      "location_summary": "Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04635800"
    },
    {
      "nct_id": "NCT04626128",
      "title": "Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "CLS-AX",
          "type": "DRUG"
        },
        {
          "name": "Anti-VEGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clearside Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-12-15",
      "completion_date": "2022-10-13",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04626128"
    },
    {
      "nct_id": "NCT06817343",
      "title": "A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)",
        "Neovascular (Wet) Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "Aflibercept (2.0 mg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Exegenesis Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2024-09-10",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 2,
      "location_summary": "Reno, Nevada • Erie, Pennsylvania",
      "locations": [
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06817343"
    },
    {
      "nct_id": "NCT03999801",
      "title": "Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RGX-314",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 865,
      "start_date": "2019-05-31",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03999801"
    },
    {
      "nct_id": "NCT01863199",
      "title": "Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neovascular Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Lucentis (Treat and extend)",
          "type": "DRUG"
        },
        {
          "name": "Lucentis every 4 weeks",
          "type": "DRUG"
        },
        {
          "name": "Lucentis every 12 weeks",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retinal Consultants of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2013-05",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2017-10-04",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 4,
      "location_summary": "Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 1 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01863199"
    },
    {
      "nct_id": "NCT03423823",
      "title": "Ziv-aflibercept Efficacy in Better Regulating AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wet Macular Degeneration",
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ziv-Aflibercept 25 MG/ML [Zaltrap]",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kapil Kapoor",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 62,
      "start_date": "2017-07-07",
      "completion_date": "2020-06-26",
      "has_results": false,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 1,
      "location_summary": "Virginia Beach, Virginia",
      "locations": [
        {
          "city": "Virginia Beach",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03423823"
    },
    {
      "nct_id": "NCT01024998",
      "title": "Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Degeneration",
        "Age-Related Maculopathies",
        "Age-Related Maculopathy",
        "Maculopathies, Age-Related",
        "Maculopathy, Age-Related",
        "Retinal Degeneration",
        "Retinal Neovascularization",
        "Gene Therapy",
        "Therapy, Gene",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "AAV2-sFLT01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2010-01-11",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-08-22",
      "last_synced_at": "2026-06-11T05:48:45.786Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Worcester, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Slingerlands",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01024998"
    }
  ]
}